What is the name of the experimental obesity drug developed by Genentech?

The experimental obesity drug developed by Genentech is named petrelintide.

How much weight did patients lose with petrelintide in the trial?

In the mid-stage trial, patients using petrelintide lost up to 10.7% of their body weight over 42 weeks.

Which company is collaborating with Roche on petrelintide?

Roche gained development rights for petrelintide through a collaboration and licensing deal with Denmark's Zealand Pharma.

Home / Health / Genentech's New Drug Sheds 10.7% Body Weight

Genentech's New Drug Sheds 10.7% Body Weight

6 Mar

•

Summary

Experimental obesity drug petrelintide achieved significant weight loss.
Patients lost up to 10.7% of body weight in a 493-patient trial.
Roche gained development rights via a deal with Zealand Pharma.

Genentech's New Drug Sheds 10.7% Body Weight

An experimental drug named petrelintide, a development from Genentech, a subsidiary of Roche, has demonstrated notable efficacy in a recent mid-stage clinical trial. The study, which included 493 participants, revealed that the drug helped individuals achieve significant weight reduction.

Over a 42-week period, patients treated with petrelintide experienced an average body weight loss of up to 10.7%. This outcome contrasts sharply with the 1.7% weight loss observed in participants who received a placebo during the same timeframe. The development of petrelintide is supported by a collaboration and licensing agreement established last year between Roche and Denmark-based Zealand Pharma, granting the Swiss company shared rights to this amylin-based obesity therapy.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.